Zobrazeno 1 - 10
of 845
pro vyhledávání: '"Streffer JR"'
Autor:
Ishii, Akihiro1 (AUTHOR), Pathoulas, Joseph A.1 (AUTHOR), MoustafaFathy Omar, Omar1 (AUTHOR), Ge, Yingying1 (AUTHOR), Yao, Annie Y.1 (AUTHOR), Pantalena, Tressa1 (AUTHOR), Singh, Neeraj1 (AUTHOR), Zhou, John1 (AUTHOR), He, Wanxia1 (AUTHOR), Murphy, Patrick2 (AUTHOR), Yan, Riqiang1 (AUTHOR) riyan@uchc.edu, Hu, Xiangyou1 (AUTHOR) xhu@uchc.edu
Publikováno v:
Molecular Neurodegeneration. 11/16/2024, Vol. 19 Issue 1, p1-18. 18p.
Autor:
Mosleh, Haideh1, Ghayyem, Hani2, Sharifpour, Sanaz3, Eyvani, Kimia4, Niknejad, Sepideh5, Davoodi, Ali5, Zarebidoki, Ameneh6, Ahmadian, Sarina7, Kohandel, Kosar8, Eghbaldoost, Amirreza9, Pour, Mehraeen Jashni10, Binaei, Sara11, Abbasi, Ali Sanaye4, Kosari, Mohammadreza12 Mh.reza.kosari@gmail.com
Publikováno v:
Caspian Journal of Neurological Sciences. Autumn2024, Vol. 10 Issue 4, p247-265. 19p.
Autor:
Novak G; Janssen Research and Development LLC, 1125 Trenton-Harbourton Rd, Titusville, NJ, 08560, USA. gnovak1@its.jnj.com., Streffer JR; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Present address: UCB Biopharma SPRL, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium., Timmers M; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Henley D; Janssen Research and Development LLC, 1125 Trenton-Harbourton Rd, Titusville, NJ, 08560, USA., Brashear HR; Janssen Research and Development LLC, 1125 Trenton-Harbourton Rd, Titusville, NJ, 08560, USA., Bogert J; Janssen Research and Development LLC, Raritan, NJ, USA., Russu A; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium., Janssens L; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium., Tesseur I; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.; Present address: UCB Biopharma SPRL, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium., Tritsmans L; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium., Van Nueten L; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium., Engelborghs S; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Department of Neurology and Center for Neurosciences, UZ Brussel and Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Publikováno v:
Alzheimer's research & therapy [Alzheimers Res Ther] 2020 May 14; Vol. 12 (1), pp. 58. Date of Electronic Publication: 2020 May 14.
Autor:
Timmers M; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. Electronic address: mtimmer3@its.jnj.com., Tesseur I; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Bogert J; Janssen Research and Development LLC, Raritan, NJ, USA., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistery Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistery Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Börjesson-Hanson A; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Sahlgrenska University Hospital, Mölndal, Sweden; Clinical Trials, Theme Aging, Karolinska University Hospital, Stockholm, Sweden., Baquero M; Neurology Department, Hospital Universitari I Politecnic La Fe, Valencia, Spain., Boada M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., Randolph C; MedAvante-ProPhase, Hamilton, NJ, USA; Department of Neurology, Loyola University Medical Center, Maywood, IL, USA., Tritsmans L; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Van Nueten L; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Engelborghs S; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Department of Neurology and Center for Neurosciences, UZ Brussel and Vrije Universiteit Brussel (VUB), Brussels, Belgium., Streffer JR; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Publikováno v:
Neurobiology of aging [Neurobiol Aging] 2019 Jul; Vol. 79, pp. 131-141. Date of Electronic Publication: 2019 Apr 01.
Tissue inhibitor of metalloproteinases I (TIMP-1) inhibits several proteinases including a disintegrin and metalloproteinase 10 (ADAM10), a major alpha-secretase that cleaves the beta-amyloid precursor protein within its amyloidogenic Abeta domain. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::741a50dec76ebf54151dc2886d5a1516
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3082323
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3082323
Autor:
Timmers M; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. mtimmer3@its.jnj.com.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. mtimmer3@its.jnj.com., Streffer JR; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Present address: Head of Translational Medicine Neuroscience, UCB Biopharma SPRL, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium., Russu A; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium., Tominaga Y; Janssen Pharmaceutical K.K, Tokyo, Japan., Shimizu H; Janssen Pharmaceutical K.K, Tokyo, Japan., Shiraishi A; Janssen Pharmaceutical K.K, Tokyo, Japan., Tatikola K; Janssen Research and Development LLC, Raritan, NJ, USA., Smekens P; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium., Börjesson-Hanson A; Sahlgrenska University Hospital, Mölndal, Sweden., Andreasen N; Department Neurobiology, Care Sciences & Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden., Matias-Guiu J; Hospital Clinic San Carlos, Universidad Complutense, Madrid, Spain., Baquero M; Neurology Department, Hospital Universitari I Politecnic La Fe, Valencia, Spain., Boada M; Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain., Tesseur I; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium., Tritsmans L; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium., Van Nueten L; Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium., Engelborghs S; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.
Publikováno v:
Alzheimer's research & therapy [Alzheimers Res Ther] 2018 Aug 23; Vol. 10 (1), pp. 85. Date of Electronic Publication: 2018 Aug 23.
Autor:
Liepelt-Scarfone I; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen, Tuebingen, Germany.; German Center for Neurodegenerative Diseases, Tuebingen, Germany., Brändle B; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen, Tuebingen, Germany.; German Center for Neurodegenerative Diseases, Tuebingen, Germany., Yilmaz R; Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany., Gauss K; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen, Tuebingen, Germany.; German Center for Neurodegenerative Diseases, Tuebingen, Germany., Schaeffer E; Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany., Timmers M; Janssen Research and Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Wurster I; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen, Tuebingen, Germany.; German Center for Neurodegenerative Diseases, Tuebingen, Germany., Brockmann K; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen, Tuebingen, Germany.; German Center for Neurodegenerative Diseases, Tuebingen, Germany., Maetzler W; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen, Tuebingen, Germany.; Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany., Van Nueten L; Janssen Research and Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Streffer JR; Janssen Research and Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Berg D; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen, Tuebingen, Germany.; Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Publikováno v:
European journal of neurology [Eur J Neurol] 2017 Nov; Vol. 24 (11), pp. 1369-1374. Date of Electronic Publication: 2017 Sep 05.
Autor:
Westwood S; Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, UK., Liu B; Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, UK., Baird AL; Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, UK., Anand S; Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, UK., Nevado-Holgado AJ; Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, UK., Newby D; Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, UK., Pikkarainen M; Institute of Clinical Medicine, Neurology, University of Eastern Finland, 70211, Kuopio, Finland., Hallikainen M; Institute of Clinical Medicine, Neurology, University of Eastern Finland, 70211, Kuopio, Finland., Kuusisto J; Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, 70211, Kuopio, Finland., Streffer JR; Janssen Research and Development, Janssen Pharmaceutics NV, Turnhoutseweg 30, 2340, Beerse, Belgium., Novak G; Janssen Pharmaceutical Research and Development, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA., Blennow K; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, SE-431 80, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 80, Mölndal, Sweden., Andreasson U; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, SE-431 80, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 80, Mölndal, Sweden., Zetterberg H; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, SE-431 80, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 80, Mölndal, Sweden.; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Smith U; Lundberg Laboratory for Diabetes Research, Department of Molecular and Clinical Medicine, Sahlgrenska Academy at the University of Gothenburg, 405 30, Gothenburg, Sweden., Laakso M; Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, 70211, Kuopio, Finland., Soininen H; Institute of Clinical Medicine, Neurology, University of Eastern Finland, 70211, Kuopio, Finland.; Neurocenter, Neurology, Kuopio University Hospital, 70211, Kuopio, Finland., Lovestone S; Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, UK. simon.lovestone@psych.ox.ac.uk.
Publikováno v:
Alzheimer's research & therapy [Alzheimers Res Ther] 2017 Apr 26; Vol. 9 (1), pp. 31. Date of Electronic Publication: 2017 Apr 26.
Autor:
Timmers M; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Barão S; VIB Center for the Biology of Disease, VIB-Leuven, Belgium.; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Belgium., Van Broeck B; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Tesseur I; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Slemmon J; Janssen Research and Development LLC, La Jolla, CA, USA., De Waepenaert K; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Bogert J; Janssen Research and Development LLC, Raritan, NJ, USA., Shaw LM; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Engelborghs S; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium., Moechars D; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Mercken M; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Van Nueten L; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., Tritsmans L; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium., de Strooper B; VIB Center for the Biology of Disease, VIB-Leuven, Belgium.; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Belgium.; Institute of Neurology, University College London, UK., Streffer JR; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Publikováno v:
Journal of Alzheimer's disease : JAD [J Alzheimers Dis] 2017; Vol. 56 (4), pp. 1437-1449.
Autor:
Papazoglou, Anna1 (AUTHOR), Henseler, Christina1 (AUTHOR), Weickhardt, Sandra2 (AUTHOR), Teipelke, Jenni1 (AUTHOR), Papazoglou, Panagiota1 (AUTHOR), Daubner, Johanna1 (AUTHOR), Schiffer, Teresa1 (AUTHOR), Krings, Damian1 (AUTHOR), Broich, Karl2 (AUTHOR), Hescheler, Jürgen3,4 (AUTHOR), Sachinidis, Agapios3,4 (AUTHOR), Ehninger, Dan5,6 (AUTHOR), Scholl, Catharina2 (AUTHOR), Haenisch, Britta2,6,7 (AUTHOR), Weiergräber, Marco1,2,3,4 (AUTHOR) marco.weiergraeber@bfarm.de
Publikováno v:
PLoS ONE. 2/7/2024, Vol. 19 Issue 2, p1-50. 50p.